Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence

Published: Tuesday, December 01, 2009
Last Updated: Tuesday, December 01, 2009
Bookmark and Share
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.

Exiqon A/S has announced that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence. ICCB-L supports investigators at Harvard Medical School, and associated hospitals and institutions, for high-throughput screening of small molecule and RNAi libraries.

ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators, coordinated by Dr. Neil Kubica of the Blenis Laboratory at Harvard Medical School.

The consortium has developed multiple biological models that will be interrogated with the Knockdown Library. The Library contains over 900 specific inhibitors designed for uniform potency, made possible through the incorporation of Exiqon's proprietary LNA™ technology.

"My colleagues and I look forward to screening the Knockdown Library. There is a great deal of interest in our community in using miRNA knockdown reagents to study disease-related biology," says Dr. Kubica.

Exiqon recently unveiled its microRNA Centers of Excellence Program - which has categories for microRNA Profiling (Expression), microRNA detection and imaging (Localization), and microRNA functional studies (Screening) - to help provide a set of reference laboratories and institutions for researchers new to the field of microRNA study.

"More and more researchers are recognizing the importance and relevance of microRNA in their own biological systems under study. But with a variety of methods and solutions from different providers, sometimes researchers aren't sure where to start. It can be overwhelming," says Tom Bishop, Site Director for Exiqon North America. "The microRNA Centers of Excellence are meant to be a roadmap of sorts for researchers new to microRNA - a panel of experts who demonstrate best-in-class tactics and approaches to microRNA studies."

The microRNA Centers of Excellence Program serves as an example of the collaborative spirit in which microRNA research has blossomed over recent years, according to Exiqon officials.

ICCB-L represents the first institution to be inducted as an Exiqon microRNA Center of Excellence, in the area of functional studies. Exiqon is currently accepting other Center of Excellence applications in all categories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Secures Funding to Accelerate Growth
Exiqon A/S has announced the issue of a senior secured note in the amount of DKK 40 million (‘Note’).
Thursday, November 12, 2015
Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.
Tuesday, June 11, 2013
Exiqon Announces 2011 Grant Program for MicroRNA Research
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.
Wednesday, February 02, 2011
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!